Long-Term Efficacy of Rasagiline in Early Parkinson's Disease

被引：32

作者：

Lew, Mark F. ^{[1
]}

Hauser, Robert A. ^{[2
]}

Hurtig, Howard I. ^{[3
]}

Ondo, William G. ^{[4
]}

Wojcieszek, Joanne ^{[5
]}

Goren, Tamar ^{[6
]}

Fitzer-Attas, Cheryl J. ^{[6
]}

机构：

[1] Keck Univ So Calif, Sch Med, Dept Neurol, Los Angeles, CA 90033 USA

[2] Univ S Florida, Dept Neurol, Tampa, FL 33620 USA

[3] Univ Penn Hlth Syst, Dept Neurol, Penn Hosp, Philadelphia, PA USA

[4] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA

[5] Indiana Univ, Sch Med, Dept Neurol, Indianapolis, IN 46202 USA

[6] Teva Pharmaceut Ind Ltd, Petah Tiqwa, Israel

来源：

INTERNATIONAL JOURNAL OF NEUROSCIENCE | 2010年 / 120卷 / 06期

关键词：

dopamine agonists; efficacy; levodopa; long-term; monotherapy; rasagiline; DOPAMINE AGONIST USE; DELAYED-START; ASSOCIATION; INITIATION;

D O I：

10.3109/00207451003778744

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

This study was designed to follow the long-term efficacy, safety, and tolerability of rasagiline for Parkinson's disease (PD) with data collected from all patients who had ever taken rasagiline during the 12-month TEMPO monotherapy trial (N = 398) and subsequent open-label extension. Patients were followed for up to 6.5 years with a mean of 3.5 +/- 2.1 years. After 12 months, additional PD medications were added as required. Of patients remaining in the trial at 2 years, 46% were maintained on rasagiline monotherapy. The majority of patients received a dopamine agonist prior to levodopa as the first additional dopaminergic agent. Analysis using a Kaplan-Meier method indicated that by 5.4 years only 25% of patients progressed to Hoehn & Yahr stage III. Rasagiline was well tolerated, with 11.3% of patients (45/398) withdrawing because of an adverse event. Rasagiline therapy for PD was effective, well tolerated, and safe in this long-term trial.

引用

页码：404 / 408

页数：5

共 12 条

[1] Treatment should not be initiated too soon in Parkinson's disease [J].

Aminoff, MJ .

ANNALS OF NEUROLOGY, 2006, 59 (03) :562-564

[2] Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed? [J].

Clarke, Carl E. .

MOVEMENT DISORDERS, 2008, 23 (06) :784-789

[3] The association of dopamine agonists with daytime sleepiness, sleep problems and quality of life in patients with Parkinson's disease - A prospective study [J].

Happe, S ;

Berger, K .

JOURNAL OF NEUROLOGY, 2001, 248 (12) :1062-1067

[4] Long-term Outcome of Early Versus Delayed Rasagiline Treatment in Early Parkinson's Disease [J].

Hauser, Robert A. ;

Lew, Mark F. ;

Hurtig, Howard I. ;

Ondo, William G. ;

Wojcieszek, Joanne ;

Fitzer-Attas, Cheryl J. .

MOVEMENT DISORDERS, 2009, 24 (04) :564-573

[5] Practice parameter: Initiation of treatment for Parkinson's disease: An evidence-based review - Report of the quality standards subcommittee of the American Academy of Neurology [J].

Miyasaki, JM ;

Martin, W ;

Suchowersky, O ;

Weiner, WJ ;

Lang, AE .

NEUROLOGY, 2002, 58 (01) :11-17

[6] Compulsive eating and weight gain related to dopamine agonist use [J].

Nirenberg, MJ ;

Waters, C .

MOVEMENT DISORDERS, 2006, 21 (04) :524-529

[7] Dopamine Dysregulation Syndrome An Overview of its Epidemiology, Mechanisms and Management [J].

O'Sullivan, Sean S. ;

Evans, Andrew H. ;

Lees, Andrew J. .

CNS DRUGS, 2009, 23 (02) :157-170

[8] Timing of treatment initiation in Parkinson's disease: A need for reappraisal? [J].

Schapira, AHV ;

Obeso, J .

ANNALS OF NEUROLOGY, 2006, 59 (03) :559-562

[9]

Siderowf A, 2002, ARCH NEUROL-CHICAGO, V59, P1937

[10]

Siderowf A, 2004, ARCH NEUROL-CHICAGO, V61, P561

← 1 2 →